Search Results for Biological Qualifier

Showing 1 – 3

Biological Products and Biosimilars: Global Naming Debate By Pallavi Trivedi - Published 27 June 2017

This article presents the contrasting views and continuing debate among health authorities in Australia, Canada, Europe, Japan and the US as well as industry experts regarding conventions for naming biological products and biosimilars. It discusses the World Health Organization's (WHO's) proposal for naming and the importance of a clear distinction between the drugs to avoid confusion and ensure patient safety.

Categories: News, Asia, Canada, Europe, Oceania, US, EMA, FDA, Health Canada, PMDA, TGA, WHO, Biologics and biotechnology, Submission and registration

Tags: Biosimilars, Biosimilar Naming, Biological Qualifier, INN

Industry, Patient Groups Weigh in on FDA's Biosimilar Naming Guidance By Michael Mezher - Published 29 October 2015

Industry is calling on the US Food and Drug Administration (FDA) to use to use "meaningful" and "distinguishable" suffixes linked to a biosimilar license holder's name, according to comments on the proposed naming system.

Categories: News, US, FDA, FTC, Biologics and biotechnology, Postmarket surveillance, Regulatory strategy, Submission and registration

Tags: Biological naming, Nonproprietary Naming of Biological Products, Biological Qualifier, Biosimilar

FDA Issues Long-Awaited Biological Product Naming Guidance By Michael Mezher - Published 27 August 2015

Today, the US Food and Drug Administration (FDA) released its long-awaited guidance establishing a naming convention for biologicals, including related and biosimilar products.

Categories: News, US, FDA, Biologics and biotechnology, Government affairs, Labeling, Postmarket surveillance, Submission and registration

Tags: Biosimilars, related biological products, naming convention, biological qualifier, suffix